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Implementation and Validation of the
2013 Caprini Score for Risk Stratification
of Arthroplasty Patients in the Prevention
of Venous Thrombosis
Eugene S. Krauss, MD, FAAOS, FACS1, Ayal Segal, MD1,
MaryAnne Cronin, MS, PharmD1 , Nancy Dengler, RN, NP1,
Martin L. Lesser, PhD2, Seungjun Ahn, MS2, and Joseph A. Caprini, MD, FACS3,4
Abstract
Appropriate chemoprophylaxis choice following arthroplasty requires accurate patient risk assessment.We compared the results
of our prospective department protocol to the Caprini risk assessment model (RAM) retrospectively in this study group. Our goal
was to determine whether the department protocol or the Caprini score would identify venous thromboembolism (VTE) events
after total joint replacement. A secondary purpose was to validate the 2013 Caprini RAM in joint arthroplasty and determine
whether patients with VTE would be accurately identified using the Caprini score. A total of 1078 patients met inclusion criteria. A
Caprini score of 10 or greater is considered high risk and a score of 9 or less is considered low risk. The 2013 version of the
Caprini RAM retrospectively stratified 7 of the 8 VTE events correctly, while only 1 VTE was identified with the prospective
department protocol. This tool provided a consistent, accurate, and efficacious method for risk stratification and selection of
chemoprophylaxis.
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Introduction
The increased risk for venous thromboembolism (VTE),
which includes deep vein thrombosis (DVT) and pulmonary
embolism (PE), is well documented following joint arthro-
plasty. Current thromboprophylaxis strategies in orthopaedic
surgery consist of a multimodal approach that includes both
chemical and mechanical options. There is agreement that
early mobilization and mechanical compression devices play
an integral role in reducing the risk of VTE. However, con-
sensus on a chemoprophylaxis regimen remains elusive and
controversial. The optimal regimen should be safe, effective,
and inexpensive. Chemoprophylaxis places the orthopaedic
patient at increased risk of postoperative bleeding and its
sequelae. These risks include wound bleeding, hematoma,
delayed wound healing, risk of dehiscence or infection, joint
stiffness, compromised functional outcome, and increased
need for an allogeneic blood transfusion.1 Thus, safety and
efficacy are of equal importance in the eyes of the orthopae-
dic surgeon.
Prior to 2012, there was disharmony among guidelines
and national quality measures with respect to appropriate che-
moprophylaxis for the arthroplasty patient. The 2007 American
Academy of Orthopaedic Surgeons (AAOS) guidelines on VTE
prevention advised the use of aspirin with a grade C recommen-
dation, acknowledging the lack of sufficient studies to identify
an optimal dose.1 In 2012, the American Academy of Chest
Physicians released their ninth edition Antithrombotic Therapy
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and Prevention of Thrombosis, with a chapter dedicated specif-
ically to prevention of VTE following orthopaedic surgery.2 This
document recognized, for the first time, the validity of aspirin for
postoperative chemoprophylaxis. In January 2014, the Centers
for Medicare and Medicaid Services added aspirin as an
“allowable value” to prevent hospital-acquired VTE following
total joint arthroplasty (TJA).3,4 The AAOS reached a consensus
recommendation on using prophylaxis for patients with addi-
tional VTE risk factors undergoing major orthopaedic surgery
but did not define these risk factors, stratify patients, or identify
specific prophylaxis agents. It did, however, acknowledge the
“appeal” of individualized risk factor assessment in choosing
a pharmacologic agent for VTE prophylaxis.1 Venous
thromboembolism prophylaxis presents the clinical dilemma of
balancing postoperative thrombotic risk along with
anticoagulation-related complications. Aspirin has been shown
to be an effective chemoprophylaxis option but in lower risk
patients.5 This emphasizes the importance of a comprehensive
risk assessment tool that can help identify the appropriate lower
risk patients for aspirin chemoprophylaxis. Although some prac-
titioners may view risk assessment as a cumbersome, time-
consuming process, Fuentes et al created a patient-friendly tool
that was shown to provide accurate patient assessment, taking
the patient 5 minutes to complete, and then on average, 6 min-
utes for the health professional to finalize.6 The importance of
completing this document prior to the operative day cannot be
overemphasized. Having the patient complete the form with
their family ahead of time and subsequently double checked
by an appropriate health-care provider are key elements in this
process. Important issues regarding family history of thrombosis
and past obstetrical complications that may reflect the presence
of the antiphospholipid syndrome are best obtained using this
process. These elements are powerful risk factors associated
with the development of postoperative thrombosis. One can
understand that the presence of these high-risk factors may influ-
ence the choice of postoperative anticoagulant prophylaxis.
Utilizing evidence-based literature, including national
guidelines1,2 and contemporary studies,5,7-10 our orthopaedic
department identified prominent VTE risk factors in order to
move to a user-friendly risk-stratification model. In August
2015, we finalized a chemoprophylaxis protocol that risk-
stratified patients to either low risk or high risk for postopera-
tive VTE. Patients were considered high risk if they met at least
one of the following criteria: VTE within prior year, morbid
obesity (body mass index [BMI] > 40) with additional comor-
bidities, active malignancy, bilateral staged joint arthroplasty,
and inherited or acquired thrombophilia. Inherited thrombophi-
lia included but was not limited to factor V Leiden, protein C
and S deficiencies, antithrombin deficiency, and prothrombin
20210A mutations; acquired thrombophilia included but was
not limited to antiphospholipid antibody syndrome (Lupus
anticoagulant, Anticardiolipin antibodies).11 Patients without
any high-risk comorbidities were considered low risk.
Using a risk stratification model based only on selected,
individual high-risk factors has limitations. The model does
not account for the cumulative effect of risk factors such as
age, weight, mobility, and certain comorbidities which could
potentially lead to undertreatment of certain patients. Further-
more, VTE chemoprophylaxis based on a weak individual risk
factor could lead to overtreatment of some patients.
The Caprini risk assessment model (RAM) has been vali-
dated in over 250 000 patients in more than 100 clinical trials
worldwide. The Caprini RAM assigns a weighted number to
various known risks factors for VTE. Risk factor weighing is
used to calculate the risk for an individual patient. These results
may be used to determine aspects of chemoprophylaxis such as
selection of the appropriate agent and duration of therapy.11
The RAM was created to track a number of important risk
factors for thrombosis, since it has been shown that as the
number of risk factors increases so does the incidence of throm-
bosis.12 Although the Caprini RAM has been validated in pre-
operative patients with hip fracture 13 as well as following foot
and ankle procedures,14 insufficient data are available to sup-
port its use in joint arthroplasty.
This study was designed to compare the Caprini RAM in the
arthroplasty patient with our department risk stratification and
chemoprophylaxis protocol. Our goal was to validate the
Caprini RAM to determine whether this is a more accurate way
to identify high-risk patients than our current department risk
stratification protocol. This will allow for a more appropriate
and individualized chemoprophylaxis regimen to lower the risk
of VTE and justify the use of anticoagulants such as direct oral
anticoagulants (DOACs) compared to aspirin in high-risk
patients. This tool can also identify those patients who are low
risk where aspirin can be effectively used.
Methods
This was a retrospective, institutional review board-approved,
cohort study of all primary total hip arthroplasty (THA), pri-
mary total knee arthroplasty (TKA), THA revision, TKA revi-
sion, and staged bilateral arthroplasty patients at a single
institution by 12 surgeons. The study period was from Septem-
ber 1, 2015, to December 31, 2016. On September 1, 2015, our
orthopaedic department adopted a chemoprophylaxis protocol
based on risk stratification. Patients were identified using a
hospital registry of all arthroplasty patients. All data were
obtained through the electronic health record. Patients were
excluded if they required therapeutic doses of anticoagulants,
had a contraindication for treatment with aspirin or a DOAC,
the arthroplasty was due to a hip fracture, or if the surgeon
opted out of the stratification-driven protocol. Staged bilateral
arthroplasty was included. The “staged” procedure, or second
side, was performed on postoperative day (POD) 5. This allows
for bilateral surgeries to be performed during 1 hospital admis-
sion, with the patient cleared for the second surgery 1 day prior
(patient must ambulate 100 feet or more; hospitalist, anesthesia
and any necessary specialists clear the patient; negative doppler
for lower extremity DVT; all blood tests and parameters are
optimized).
The chemoprophylaxis protocol based on department risk
stratification was consistent for all patients. Patients were
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risk stratified on POD 0. The only cause for change in risk
classification was cancellation of a staged case. Standardiza-
tion of VTE chemoprophylaxis did not allow for surgeon bias
in drug selection. Chemoprophylaxis was started on the morn-
ing of POD 1. The THA, THA revision, TKA, and TKA revi-
sion patients assessed as low risk were prescribed enteric
coated (EC) aspirin 325 mg twice daily for 6 weeks. The THA
and THA revision patients assessed as high risk were pre-
scribed prophylactic doses of a DOAC (rivaroxaban or apixa-
ban) for 35 days (per prescribing information).15,16 The TKA
and TKA revision patients assessed as high risk were pre-
scribed prophylactic doses of a DOAC (rivaroxaban or apixa-
ban) for 12 days (per prescribing information)15,16 followed by
EC aspirin 325 mg twice daily for 4 weeks for a total of 6 weeks
of chemoprophylaxis. Incidence of VTE following TJA
remains elevated for 5 to 6 weeks (specifically, 35 days) post-
operatively, and our surgeons advocate the need for extended
prophylaxis.17,2 Concurrent antiplatelet agents were permitted.
High-risk patients prescribed daily low-dose aspirin therapy
prior to surgery were continued on aspirin concurrently with
the DOAC; however, the dosage did not exceed 81 mg daily.
Rivaroxaban was the treatment option used in 2015. In January
2016, apixaban replaced rivaroxaban as the protocol-driven
DOAC for high-risk patients based on emerging safety data
showing lower incidence of bleeding with apixaban versus
rivaroxaban.18,19 All chemoprophylactic decisions were based
solely on the department protocol, and the Caprini score was
calculated by retrospective chart review.
The Caprini RAM version 2013 was utilized for this study20
(Figure 1). This version differs from preceding versions in that
it includes additional risk factors not tested in validation studies
but shown in the literature to be associated with thrombosis.
These identified risk factors include BMI above 40,21,22 smok-
ing,23,24 diabetes requiring insulin,25,26 chemotherapy,27,28
blood transfusions,29,30 and length of surgery over 2 hours.31,32
The Caprini RAM was completed by specially trained medical
students via review of the presurgical assessment history, med-
ical clearances, medical consults, and hospital charts. The
Caprini RAM was completed for every participant both preo-
peratively and predischarge to ensure that any changes in the
patient’s postoperative course were captured by the tool. The
statistical analysis for the Caprini score was evaluated using the
final predischarge Caprini score. The Caprini RAM was com-
pleted retrospectively and therefore had no influence on che-
moprophylaxis selection. Ultimately, we sought to validate a
risk assessment schema that would best identify high-risk
patients who would benefit from traditional anticoagulants.
Preoperative and postoperative protocols were consistent for
all patients. Spinal anesthesia was used unless there was a
medical contraindication. Intravenous or intra-articular tran-
examic acid (TXA) was administered in the operating room
(OR) unless the patient had an inherited or acquired thrombo-
philia or an allergy to TXA. Intermittent pneumatic compres-
sion devices were applied in the OR and continued
postoperatively while the patient was in bed. Early ambulation
following joint arthroplasty began on POD 0. Patients were
seen by a physical therapist within 4 hours of discharge from
the post-anesthesia care unit and began their ambulation. Only
acute medical events were a valid reason to postpone early
ambulation on POD 0.
The primary efficacy outcomes were (1) symptomatic VTE
events confirmed by objective testing, (2) all-cause mortality, and
(3) return to the OR for a bleeding event, all within 60 days of
surgery. Routine duplex ultrasounds were only performed on
stagedcases thedayprior to the secondarthroplasty.The incidence
of PE, symptomatic DVT, return toOR for bleeding, and all-cause
mortality were identified using a prospectively maintained
database. The DVT was classified as either proximal or distal.
Major bleeding was defined as a postoperative drop in hemo-
globin (Hgb) of 2g/dL or the administration of 2 units of
autologous red blood cell transfusions. Postoperatively medical
care was managed by the hospital, a medical doctor specializing
in the care of hospitalized patients. The blood transfusion pro-
tocol was consistent for all patients. Patients received allogeneic
blood transfusions when the Hgb was7 g/dL. For Hgb >7 g/dL
to <8 g/dL, patients were treated only if they were exhibiting
clinical symptoms related to the anemia or if there was a rapid
decline in Hgb. For Hgb 8 g/dL, patients were treated if they
were exhibiting clinical symptoms of anemia.
Statistical Analysis
The primary objective was to characterize the degree of asso-
ciation between Caprini score and the department risk stratifi-
cation classification. Using the risk stratification category as
the “reference gold standard,” a Caprini “cutoff” point could be
determined that would maximize sensitivity and specificity.
Univariable logistic regression analysis with Caprini score as
a predictor and risk stratification as binary outcome (high or
low) was carried out. Analysis of the resulting receiver–oper-
ating characteristic curve (ROC) was performed to identify the
optimal cutoff Caprini score based on Youden index.33 The
Youden index is a measure of the discriminatory performance
of a decision rule, compared to that of simply flipping a coin.
The Caprini score corresponding to the largest Youden index
was considered as the optimal cutoff value. Based on this cut-
off, sensitivity and specificity of the Caprini score relative to
risk stratification were computed.
The obtained cutoff Caprini score was also used to compute
the sensitivity and specificity and corresponding 95% confi-
dence intervals (CIs) for VTE occurrence.
Summary statistics for the study sample are presented as
median, lower quartile, and upper quartile for measured vari-
ables and frequencies with percentages for categorical vari-
ables. Analysis was conducted using SAS version 9.4 (SAS
Institute, Inc, Cary, North Carolina).
Results
The retrospective chart review identified 1078 patients who
met inclusion criteria (Table 1). The distribution of the final
Caprini Score is shown in Figure 2. The final predischarge
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Figure 1. Caprini risk assessment model (version 2013).
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Caprini score differed from the preoperative score for 78
(7.2%) patients. The change in score was due to blood transfu-
sions, a postoperative brace, restricted mobility, and cancella-
tion of a staged case. Restricted mobility was defined as
inability to ambulate continuously more than 30 feet and also
was applied to any patient who was unable to ambulate using
both leg muscles.34 The dynamic, changeable nature of the
score is a critically important feature of the Caprini RAM.
The area under the ROC curve was 0.896 (95% CI: 0.874-
0.917). The largest Youden index was 0.632, and the corre-
sponding optimal cutoff Caprini score was 10. In other words,
patients with a Caprini RAM score of 10 or greater are consid-
ered high risk and a score of less than 10 are considered low
risk. Based on this cutoff, among the 281 high-risk patients,
234 had a score of 10 or greater yielding a sensitivity of 83%
(95% CI: 78%-87%). Similarly, among the 797 low-risk
patients, 637 had a score <10 yielding a specificity of 80%
(95% CI: 77%-83%; Table 2).
There were 8 patients with symptomatic VTE. There was 1
distal DVT with a CVA in a patient with a newly diagnosed
patent foramen ovale, 2 PEs without DVT, 1 proximal DVT,
and 4 distal DVTs. Seven of the VTE events were correctly
identified as high risk with a Caprini RAM score of 10 or greater,
while 7 of the same study patientswere considered low risk byour
department protocol (Table 3). Of note, the patient who sustained
a PE but was considered low risk by department protocol as well
as by Caprini scoring (8) was found to have an undiagnosed
thrombophilic defect upon hematology workup after developing
a second, unprovoked PE months later. If this was known pre-
operatively, the patient’s score would have been 11. This would
have resulted in the Caprini score correctly identifying 100% of
patients experiencing a VTE. Finally, no staged bilateral arthro-
plasty patients experienced a postoperative thrombus.
There were no deaths during the 60-day follow-up period.
Bleeding analysis included 937 patients. A total of 141 patients
were excluded from this analysis. Exclusions included staged
cases due to 2 surgeries in 5 days, patients missing POD1
laboratory test results, and patients taking more than 1 antipla-
telet agent as these were confounding factors. No patients
returned to the OR for bleeding. Bleeding outcomes were not
different between the groups: aspirin alone (reference group, n
¼ 745, odds ratio [OR]: 1.00), aspirin plus concurrent antipla-
telet agent (n ¼ 45, OR: 2.15, 95% CI: 0.81-5.73; P ¼ .127),
apixaban or rivaroxaban alone (n ¼ 98, OR: 0.73, 95% CI:
0.26-2.09; P ¼ .558), apixaban or rivaroxaban plus aspirin 81
mg (n ¼ 49, OR: 0.73, 95% CI: 0.17-3.11; P ¼ .671).
Caprini risk factors relevant to this patient sample were
extracted from the Caprini RAM to ascertain their associations
with the department risk stratification protocol (Table 4).
Sensitivity and specificity for the departmental protocol
were 0.12 (exact 95% CI: 0-0.53) and 0.74 (95% CI: 0.71-
0.77), respectively (Table 5). Sensitivity and specificity for the
Caprini score were 0.88 (exact 95% CI: 0.47-1.00) and 0.64
(95% CI: 0.61-0.67), respectively (Table 6).
Discussion
It is estimated that 900 000 VTE events resulting in 100 000
premature deaths occur annually in the United States.35 Both
DVT and PE are known complications following TJA, often
resulting in significant morbidity and mortality as well as the
associated economic burden to the patient and the health-care
system.36 The orthopaedic surgeon is as concerned with postsur-
gical bleeding as they arewith thrombosis, and thus, the challenge
persists in the prevention of these complications. Chemoprophy-
laxis choice should be both safe and effective. To date, no risk
assessment methodology has been validated for the TJA patient.
Table 1. Baseline Characteristics: Department Risk Stratification
Protocol.a
Criteria
Low Risk Aspirin,
N ¼ 797
High Risk (DOAC),
N ¼ 281
THA 295 (37.0) 46 (16.4)
TKA 449 (56.3) 106 (37.7)
Revision THA 20 (2.5) 1 (0.4)
Revision TKA 32 (4.0) 5 (1.8)
Staged bilateral THA 0 (0.0) 23 (8.2)
Staged bilateral TKA 1 (0.1)b 100 (35.6)
Age, years 67.0 (60.0-74.0) 65.0 (58.0-71.0)
Gender, No. (%) M ¼ 322 (40.4) M ¼ 89 (31.7)
F ¼ 475 (59.6) F ¼ 192 (68.3)
BMI 29.6 (26.2-33.2) 35.8 (29.0-41.9)
Abbreviations: BMI, body mass index; DOAC, direct oral anticoagulant; THA,
total hip arthroplasty; TKA, total knee arthroplasty.
aData are presented as median (lower quartile, upper quartile) for continuous
variables, and number (%) for categorical variables above.
bPatient requested aspirin only.
Figure 2. Distribution of final (Predischarge) Caprini score.
Table 2. Frequency Table of Department Risk Stratification Versus
Cutoff Caprini Score of 10 or Greater.
Caprini Score
Department Protocol
High Risk
Department Protocol
Low Risk Total
Caprini 10 234 (Sens ¼ 83%) 160 394
Caprini <10 47 637 (Spec ¼ 80%) 684
Total 281 797 1078
Abbreviations: Sens, sensitivity; Spec, specificity.
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Bateman et al, in a retrospective review, evaluated the correla-
tion of the Caprini RAM and VTE incidence following primary
TJA in 363 patients. The authors found that the CapriniRAMwas
not a clinically useful tool for TJA patients.37 Our review of this
publication noted some deficiencies with the completion of the
Caprini score. In this article, the preoperative scores were cor-
rectly completed only 7% of the time. The authors admitted this
was a major concern and they explained this discrepancy was
mainly due to incomplete documentation of medical comorbid-
ities and technical error. We feel that for the Caprini tool to be
useful in any study, complete data are a prerequisite.
TheCaprini RAM is a dynamic tool requiring ongoing evalua-
tion of a patient during their hospital course and the postoperative
recovery period. Conversely our department risk stratification
protocol was a static tool and thereby did not account for changes
in patient status after surgery. Cancellation of a staged case was
the only cause for change in risk assessment. This was an inherent
fault of the department risk stratification protocol. Continuous
evaluation is necessary, as changes in clinical status can result
in a change in the score, necessitating an alternate treatment
option. Bateman et al completed the Caprini RAM preopera-
tively, thereby excluding from review any change in the patient’s
status during the postoperative period.37 Postoperative occur-
rences such as blood transfusions, braces, or impaired mobility
would increase theCaprini score,warranting further reassessment
for appropriate chemoprophylaxis.
Further, bilateral cases were calculated inaccurately. Patients
undergoing bilateral or staged cases should be assessed a value of
“10” for elective hip or knee arthroplasty as they are undergoing
“2” procedures within a month. These authors calculated the
Caprini score as 7.9 (+1.4), thereby giving the same assessment
for a bilateral arthroplasty as a unilateral procedure.
In a response letter to the editor of the Journal of Arthro-
plasty from the Caprini group, Bateman et al did not recognize
the value of risk stratifying the joint arthroplasty patient pop-
ulation, as they are all categorized as high risk with a score of 5
points.38 This assumption is based on conclusions drawn by
Gould et al, in the 2012 CHEST guidelines for prevention of
VTE in nonorthopaedic surgical patients, categorizing any
patient with a Caprini score of 5 points or greater as high risk.39
Table 3. VTE Events.
VTE Event Procedure Age/Gender Preop Department Risk Stratification
Discharge Caprini
Risk Classification VTE Prophylaxis
CVA(PFO) Distal DVT TKA 72/M Low 11 High Aspirin
PE 1 TKA 67/F High 11 High Apixaban
PE 2 TKA 60/F Low 8 Lowa Aspirin
Proximal DVT THA 57/F Low 12 High Aspirin
Distal DVT TKA 77/M Low 11 High Aspirin
Distal DVT TKA 80/M Low 11 High Aspirin
Distal DVT TKA 81/F Low 10 High Aspirin
Distal DVT THA 69/F Low 10 High Aspirin
Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism; THA, primary total hip; TKA, primary total knee; VTE, venous thromboembolism.
aPatient later found to have thrombophilic defect which would have resulted in a score of 11, Caprini high-risk group.
Table 4. Caprini Risk Factors.a
Caprini Risk Factors (%)
Department
Protocol Low Risk
Aspirin, N ¼ 797
Department
Protocol High Risk
(DOAC), N ¼ 281
BMI >40 11 (1.4%) 105 (37.4%)
Current or past
malignancies
108 (13.6%) 54 (19.2%)
Chemotherapy 6 (0.8%) 5 (1.8%)
Age >75 183 (23.0%) 40 (14.2%)
History DVT or PE 10 (1.3%) 28 (10.0%)
Family history blood clots 22 (2.8%) 12 (4.3%)
Personal or family history
of positive blood test for
thrombophilia
1 (0.1%) 18 (6.4%)
Abbreviations: BMI, body mass index; CVA, cerebrovascular accident; DOAC,
direct oral anticoagulant; DVT, deep vein thrombosis; PE, pulmonary embo-
lism; PFO, patentforamen ovale.
aData are presented as a number (%) for categorical variables above.
Table 5. Frequency Table of VTE Versus Department Protocol .
Risk Category VTE No VTE Total
Department high risk 1 (Sens ¼ 12%) 278 279
Department low risk 7 792 (Spec ¼ 74%) 799
Total 8 1070 1078
Abbreviations: Sens, sensitivity; Spec, specificity.
Table 6. Frequency Table of VTE Versus Cutoff Caprini Score of 10
or Greater.
Caprini Score VTE No VTE Total
Caprini 10 7 (Sens ¼ 88%) 387 394
Caprini <10 1 683 (Spec ¼ 64%) 684
Total 8 1070 1078
Abbreviation: Sens, sensitivity; Spec, specificity; VTE, venous
thromboembolism.
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Dismissing the use of the Caprini RAM in this patient popula-
tion does not allow for identification of patients who would be
considered “very high risk.” This very high-risk stratification
has been successfully recognized in other surgeries. Cassidy
et al found that a Caprini score of 8 or greater was considered
very high risk for general and vascular surgery, and these
patients benefited from 30 days of postoperative low-
molecular weight heparin prophylaxis.40 Pannucci et al, in a
meta-analysis, found that patients with Caprini scores of 7 to 8
(OR: 0.60, 95% CI: 0.37-0.97) and >8 (OR: 0.41, 95% CI: 0.26-
0.65) had significant VTE risk reduction after surgery with
chemoprophylaxis.12 The incidence of VTE in those not receiv-
ing anticoagulant prophylaxis escalated in proportion to the
score (Figure 3).
Finally, Luksameearunothai et al, in a study of patients with
hip fracture, found that a Caprini score of 12 or greater was
associated with a high incidence of preoperative DVT (16.3%).
The authors recommended preoperative scans in those with these
high scores, since the DVT group showed a significantly higher
Caprini score compared to the non-DVT group (P < .05). Further-
more, the sensitivity and specificity associated with a Caprini
score 12 points were 93% and 35%, and those with a Caprini
score 13 points were 60% and 73%, respectively.13
In the current study, we found that a Caprini score of 10 or
greater is considered very high risk. The authors agree that all
joint arthroplasty patients are high risk for postoperative VTE
and require chemoprophylaxis. With the current availability of
multiple treatment options, the identification of very high-risk
patients is more imperative than ever. The challenge is to
choose the right drug for the appropriate patient.
The ability to risk stratify patients allows us to safely choose
distinct chemoprophylaxis agents for postoperative VTE.
Aspirin 325 mg twice daily was chosen for our low-risk chemo-
prophylaxis treatment protocol based on the 2007 AAOS guide-
lines as well as current literature when the protocol was created.
Recent publications have demonstrated both the safety and the
efficacy of lower doses of aspirin. Anderson et al, in a large,
randomized, double-blind trial, demonstrated the safety and effi-
cacy of aspirin or rivaroxaban for VTE prophylaxis for hip and
knee arthroplasty patients.41 This was the first clinical trial to
compare aspirin to a DOAC in the orthopaedic population. How-
ever, Garcia, in an accompanying editorial, discussed limitations
that could prevent universal adoption of this treatment protocol.
Garcia noted that since “relatively few patients with previous
VTE, morbid obesity, or cancer underwent randomization, we
cannot be certain how the 2 prophylaxis strategies would per-
form in these very high-risk populations,”42 further highlighting
the necessity of individualized risk stratification.
Parvizi et al, in a comparative prospective study, demon-
strated that 4 weeks of treatment with low dose of aspirin (81
mg twice a day), both plain and EC, is not inferior to a higher
dose of EC aspirin (325 mg twice a day) in the prevention of
VTE.43 However, this study excluded patients felt to be at high
risk for VTE based on the authors’ modeling system. This
model was based on a scoring system whereby patients were
stratified to high and low risk. The predictors identified with
the highest points were hypercoagulability, metastatic cancer,
stroke, sepsis, and chronic obstructive pulmonary disease.44
These risk factors are all identified in the Caprini RAM.
Comprehensive assessment of the VTE events revealed that
occurrence of thrombosis was not influenced by individual
high-risk factors, but the cumulative effect of multiple factors
that increased the patient’s Caprini score. The unique feature of
the Caprini score is that certain risk factors are more heavily
weighted than others. Therefore, the synergistic effect of indi-
vidual factors of varying significance, when combined, yield a
predictive score which is more accurate than any individual
factor. Seven of the 8 VTE events were correctly identified
as high risk with a Caprini RAM score of 10 or greater, while
the same 7 study patients were considered low risk by our
department risk stratification protocol. The patient suffering a
PE postoperatively would have been placed in the high-risk
Caprini group with a score of 11 if the thrombophilia had been
known. Using the Caprini RAM in the arthroplasty patient
allows for quantification of patient risk factors. This provides
for an accurate patient-centered treatment regimen based on a
consistent RAM. As the Caprini RAM is a dynamic tool, con-
tinuous monitoring of VTE risk factors is essential in the
extended postoperative period. In our study, the mean baseline
preoperative score was 9; therefore, additional risk factors
could easily increase the cumulative score to 10 or more.
Accurate, consistent completion of the 2013 Caprini RAM
imperative for this study. The Caprini RAM in our study was
completed by trained medical students. Any questions or con-
cerns regarding scoring were escalated to Dr Caprini. This
process led to the development of completion guidelines to
ensure consistency and accuracy of the scoring. The final
Caprini RAMs were reviewed by one person and any issues
or discrepancies were adjudicated by Dr Caprini.
This is a retrospective study, therefore limiting extrapola-
tion of findings. This may be viewed as a weakness. It may also
be a strength as no patient was excluded from review. Retro-
spective database reviews have flaws since it is not known if all
of the questions were presented to the patient and to their level
of understanding.45 Family history is often overlooked during
Figure 3. VTE in surgical patients who received no chemoprophy-
laxis, stratified by Caprini score.
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the history process. A history of past VTE or family VTE
history is one of the most powerful risk factors responsible for
postoperative thrombosis.46 Unknown or unreported history is
always an issue of significance when taking an accurate history
and physical. This was evident with the one patient who was
assessed as low risk by both the department protocol and the
Caprini score. We have subsequently developed a patient
friendly form to address this challenge.
Conclusion
The 2013 version of the Caprini RAM correctly identified all
but one of the arthroplasty patients who developed a clinical
VTE event (8/1078). This tool provided a consistent, accurate,
and efficacious method for risk stratification. The Caprini
RAM is a dynamic tool, requiring ongoing evaluation of the
patient during their hospital course and the postoperative
recovery period. Changes in clinical status could result in a
change in the score, thereby resulting in a new score and poten-
tially a revised treatment option. Using the 2013 Caprini scor-
ing system in the arthroplasty patient will allow for an
individualized chemoprophylaxis treatment assignment justify-
ing the use of a DOAC compared to aspirin in those with a high
risk of thrombosis.
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